Cabozantinib for previously treated advanced hepatocellular carcinoma

Equality Impact Assessment (Guidance development) (PDF 146 KB)

Register of interests (PDF 150 KB)

Final draft guidance: TA849

Final appraisal document (PDF 196 KB)

Committee papers (PDF 5.34 MB)

Public committee slides (PDF 973 KB)

Final scope (PDF 184 KB)

Final stakeholder list (PDF 212 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 424 KB)

Equality impact assessment (Scoping) (PDF 122 KB)

Draft scope post referral (PDF 199 KB)

Draft matrix post referral (PDF 211 KB)

Final scope - TA582 (PDF 259 KB)

Final stakeholder list - TA582 (PDF 304 KB)

NICE's response to comments on the draft scope and provisional stakeholder list - TA582 (PDF 307 KB)

Equality impact assessment (Scoping) - TA582 (PDF 171 KB)

Draft scope post referral - TA582 (PDF 358 KB)

Draft matrix post referral - TA582 (PDF 304 KB)